Safety and Efficacy Results from CLI120-001 a Phase 1 Study in RR-AML and HR-MDS: Update from Higher Dose Levels
Ewa Lech‐Marańda(Instytut Hematologii i Transfuzjologi), Jan Maciej Zaucha(Gdańsk Medical University), Tomasz Rzymski, Scott R. Solomon(Northside Hospital), Kamil Kuś, Elżbieta Patkowska(Institute for Transfusion Medicine), Gautam Borthakur(The University of Texas MD Anderson Cancer Center), Agnieszka Sroka‐Porada, Hendrik Nogai, Terrence Bradley(University of Miami Health System), Paweł Steckiewicz(Holy Cross University), Howard A. Burris(Deaconess Hospital), P. B. Littlewood(University of St Andrews), Elie Mouhayar(The University of Texas MD Anderson Cancer Center), Axel Glasmacher(University Hospital Bonn), Noemi Angelosanto, Sylwia Kościółek- Zgódka(Holy Cross University), Agata Szymańska(Gdańsk Medical University), Natalia Jakacka(Instytut Hematologii i Transfuzjologi), Camille N. Abboud(Washington University in St. Louis), Renata Dudziak
Cited by 1
Related Papers
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
|Nature|2014|2.4k
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k
EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2008|951